Scope and claims analysis for US Patent 10,464,938 and the US patent landscape around Formula 2J toluenesulfonate (5-HT2 antagonists)
US 10,464,938 is a US-composition and use patent that claims a specific chemical entity defined by “Formula 2J” when presented as a toluenesulfonic acid (tosylate) salt (and also covers the free base and salt embodiments). The claimed therapeutic activity is antagonism of 5-hydroxytryptamine (serotonin) receptor 2, including receptor 2A modulation. The enforceable claim scope is driven primarily by (1) the parameterized structure of Formula 2J (k=m=n=1, R1=4-(4-fluorophenyl)-4-oxobutyl, R10=CH3, X=—N—, and multiple H substituents) and (2) the acid counterion being toluenesulfonic acid, including explicit “toluene sulfonic acid addition salt” language.
H1. US Patent 10,464,938 scope: toluenesulfonic acid salt of Formula 2J for 5-HT2 receptor antagonism
H2. What are the key claim elements in US 10,464,938 (Formula 2J tosylate and 5-HT2 receptor use)?
Answer: The independent claim (claim 1) requires a pharmaceutical composition containing (a) toluenesulfonic acid and (b) the compound of Formula 2J (or a pharmaceutically acceptable salt). Dependent claims lock in the free base and toluenesulfonic acid addition salt, plus a stoichiometric ratio feature. Method claims then tie administration to antagonizing 5-HT2 receptors and modulating 5-HT2A.
Claim 1: independent composition coverage
Claim 1 recites:
- Composition: “A pharmaceutical composition comprising toluenesulfonic acid and the compound of Formula 2J…or a pharmaceutically acceptable salt thereof.”
- Formula constraints for Formula 2J (hard structural limitations):
- k=1, m=1, n=1
- R1 = 4-(4-fluorophenyl)-4-oxobutyl
- R5 = H
- R6a = H; R6b = H
- R7 = H; R8 = H; R9 = H
- R10 = CH3
- X = —N—
- Salt language within claim 1: “compound of Formula 2J…or a pharmaceutically acceptable salt thereof” does not restrict the salt type in claim 1; however, claim 1 also requires the presence of toluensulfonic acid in the composition, which typically operationalizes as a tosylate counterion. Dependent claim 4 makes the tosylate explicit.
Practical enforcement pivot: claim 1 is structurally narrow (only the specific Formula 2J instantiation) but is compositionally broad in that it covers “compound … or a pharmaceutically acceptable salt thereof” while still requiring toluenesulfonic acid in the composition.
Claims 2–5: embodiment tightening for free base vs tosylate
- Claim 2: compound is the free base of Formula 2J.
- Still requires claim 1’s presence of toluenesulfonic acid (because claim 2 depends on claim 1). That creates a claim construction tension: the compound is free base, yet the composition contains toluenesulfonic acid. The claim language supports scenarios where tosylate is present as an excipient/acid component without converting the active to the tosylate salt, or where the product form involves both.
- Claim 3: compound is a pharmaceutically acceptable salt of Formula 2J.
- Claim 4: that salt is specifically a toluene sulfonic acid addition salt (tosylate).
- Claim 5: the composition comprises toluenesulfonic acid and the compound in a specified stoichiometric ratio (ratio not enumerated in the text provided). This adds a manufacturing/formulation precision element that can matter in infringement and in design-around.
Claim 6–11: therapeutic use (5-HT2 antagonism / 5-HT2A modulation)
These depend on claims 2 or 3 or 4, tying the administration to the free base, unspecified pharmaceutically acceptable salt, or the tosylate salt.
- Claim 6–8: “antagonizing 5-hydroxytryptamine 2 receptors”
- Claim 9–11: “modulating 5-hydroxytryptamine receptor 2A activity”
Because the only difference among the sets is the salt form referenced (claim 2 vs 3 vs 4), the method claims can be attacked or defended based on whether the administered API is the free base, another salt, or specifically the tosylate.
Claim 12: a second independent composition claim in provided set
Claim 12 (as provided) recites a composition comprising “a toluenesulfonic acid addition salt of the compound of Formula 2J” with the same structural parameter set. In effect, claim 12 reinforces the tosylate-specific composition boundary.
H2. How does the parameterized “Formula 2J” limit infringement under US 10,464,938?
Answer: Infringement turns on whether the accused product contains the exact Formula 2J instantiation with the specified substituent set: k=m=n=1; R1 is 4-(4-fluorophenyl)-4-oxobutyl; R10 is CH3; X is —N—; and multiple positions are explicitly H.
Structural “must-match” features from the claim text
The claim hard-codes:
- Core substitution pattern via k, m, n, and R-group definitions
- R1 side chain fixed to a 4-fluorophenyl-4-oxobutyl group
- X fixed to —N—
- R10 fixed to CH3
- R5–R9 fixed to H patterns (R5=H; R6a/H; R6b/H; R7=R8=R9=H)
Design-around surface
- Changing the R1 side chain away from 4-(4-fluorophenyl)-4-oxobutyl
- Changing X away from —N—
- Changing R10 away from CH3
- Changing the k/m/n values away from 1/1/1
- Altering tosylate counterion presentation: using a different salt type (if the claim is constrained to tosylate in a particular dependent claim), or using a salt form not encompassed by “toluene sulfonic acid addition salt” when claim 4/8/11/12 are targeted
H2. Does US 10,464,938 cover tosylate only, or also other salts and free base formulations?
Answer: It covers:
- Tosylate explicitly (claims 4, 8, 11, and 12)
- Free base in a composition containing toluenesulfonic acid (claim 2)
- Other pharmaceutically acceptable salts in a composition containing toluenesulfonic acid (claim 3)
Claim-by-claim salt coverage table (based on provided claim set)
| Claim |
API form requirement |
Counterion / acid requirement in composition |
Practical scope |
| 1 |
Formula 2J “or a pharmaceutically acceptable salt thereof” |
toluenesulfonic acid required |
Broad across salt forms but still requires toluenesulfonic acid present |
| 2 |
Formula 2J free base |
toluenesulfonic acid required |
Covers formulations where tosylate acid coexists without full salt conversion |
| 3 |
Formula 2J other pharmaceutically acceptable salt |
toluenesulfonic acid required |
Captures non-tosylate salts if tosylate acid remains part of the composition |
| 4 |
Formula 2J toluene sulfonic acid addition salt |
toluenesulfonic acid required (inherent in tosylate salt) |
Tosylate-specific boundary |
| 6–7 |
Method with claim 2/3 |
as per dependent claim |
Method scope shifts with API form |
| 8 |
Method with claim 4 |
tosylate salt administered |
Tosylate-specific method coverage |
| 9–11 |
Method with claim 2/3/4 |
as per dependent claim |
5-HT2A modulation tied to salt form |
| 12 |
Composition with tosylate salt |
toluenesulfonic acid addition salt |
Reinforces tosylate composition coverage |
H2. What therapeutic scope is claimed: 5-HT2 antagonism and 5-HT2A modulation?
Answer: The patent claims medical-use methods tied to:
- antagonizing 5-hydroxytryptamine 2 receptors (5-HT2)
- modulating 5-hydroxytryptamine receptor 2A activity (5-HT2A)
How breadth is allocated
- “5-HT2 receptors” is broader than 5-HT2A alone.
- The claims separately recite 2A modulation, supporting coverage for indications or labeling centered on 2A activity.
Litigation leverage based on salt-dependent method claims
If an accused product uses the same Formula 2J but in a different salt, infringement may hinge on whether method claims keyed to claim 4 (tosylate) are met. Composition claims may be easier to trigger if toluenesulfonic acid is present as required by claim 1.
H2. What formulations are protected by US 10,464,938 (stoichiometric ratio, free base, salts)?
Answer: The protected formulation space includes:
- compositions with toluenesulfonic acid and the specified Formula 2J (claim 1)
- free base Formula 2J co-formulated with toluenesulfonic acid (claim 2)
- pharmaceutically acceptable salts of Formula 2J co-formulated with toluenesulfonic acid (claim 3)
- tosylate salt specifically (claim 4 and claim 12)
- a stoichiometric ratio requirement (claim 5)
Stoichiometric ratio feature (claim 5)
Claim 5 adds a quantitative constraint not detailed in the excerpt. If the issued patent specifies a defined ratio (e.g., 1:1 molar), that can:
- limit literal infringement to compositions matching the exact stoichiometry
- create a formulation design-around risk by shifting the salt:acid ratio, if the claim is interpreted strictly
H2. How strong is the patent estate for Formula 2J tosylate: what can be inferred from claim structure alone?
Answer: The enforceable scope of US 10,464,938 is strong on target identification (hard-coded substituent set) and medium on commercial breadth (depends on salt form and whether toluenesulfonic acid is present). It is weaker against products that change the core structure of Formula 2J or that do not include toluenesulfonic acid and/or administer a non-tosylate API when the method claims are invoked.
Claim scope drivers
- High specificity: multiple R-group and linker constraints reduce the chance that unrelated compounds are captured.
- Salt ambiguity in claim 1: “pharmaceutically acceptable salt thereof” plus requirement for toluenesulfonic acid can broaden infringement arguments for composition products.
- Salt specificity in dependent claims: claims 4/8/11/12 narrow to tosylate for method and certain composition embodiments.
H2. What patents typically cover around US 10,464,938 (process, polymorphs, intermediate salts, and additional salt forms)?
Answer: In practice, the landscape around a specific “Formula J” compound and its tosylate formulation usually fragments across:
- active ingredient compound patents (core structure and stereochemistry)
- salt formation patents (tosylate vs other acids)
- formulation patents (tablet/capsule/film coating, dose forms)
- manufacturing and process patents (crystallization conditions, solvent systems)
- polymorph/hydrate solvates patents (crystal form control)
- method-of-use patents (receptor antagonism claims, disease/indication claims)
However, no other patent numbers, assignees, or related family members are provided in the prompt. Without external patent-family data, the only defensible analysis is claim-by-claim scope of US 10,464,938 itself.
H2. When does US 10,464,938 lose exclusivity and how do data exclusivity and patent term affect generic entry risk?
Answer: Exclusivity and launch timing cannot be determined from the provided information. Patent-term and exclusivity depend on filing date, patent term adjustment, maintenance status, and any FDA exclusivity periods tied to the specific listed drug, none of which are included in the prompt.
H2. What is the Orange Book status of the drug covered by US 10,464,938?
Answer: Orange Book status cannot be concluded from the provided claim text. Orange Book listings require linkage to a specific FDA NDA/BLA and listed drug product, which is not provided.
H2. Which companies are challenging the patent via Paragraph IV, and what settlements affect enforcement?
Answer: No Paragraph IV filings, defendants, or settlement agreements are included in the prompt. A company-by-company litigation landscape cannot be generated from the claim text alone.
H2. Biosimilar risk vs generic risk for a small-molecule 5-HT2 antagonist: does this patent fall into one bucket?
Answer: The claims read as a small-molecule composition and method-of-use patent (chemical salt/free base, toluenesulfonic acid addition salt). That aligns with generic entry risk rather than biosimilar risk, but an actual categorization depends on the marketed product’s regulatory status and active ingredient identity.
H2. How does the claim scope compare with alternative salt patents for the same Formula J scaffold?
Answer: US 10,464,938’s comparative boundary is the toluenesulfonic acid requirement and the exact Formula 2J instantiation. Competing salt patents for the same scaffold would typically:
- cover different counterions (e.g., HCl, mesylate, fumarate)
- broaden or narrow method claims by tying to those specific salts
- include stoichiometry or polymorph/crystal form constraints
Within the provided claim set:
- tosylate-specific coverage is explicit (claim 4 and claim 12)
- other-salt coverage is only present when toluenesulfonic acid remains part of the composition (claims 1 and 3)
H2. What generic launch scenarios are most likely to avoid infringement of US 10,464,938?
Answer: From claim language, the most plausible avoidance routes are:
- Use a different active ingredient structure than the claimed Formula 2J instantiation (alter R1, X, R10, or k/m/n)
- Administer Formula 2J in a salt form where no toluenesulfonic acid is present in the composition, to argue non-meeting of claim 1’s toluenesulfonic acid requirement
- For method claims keyed to tosylate, administer a non-tosylate salt and avoid any product form that would be construed as a toluenesulfonic acid addition salt
H2. Which claim features are easiest to challenge (in validity or infringement) based on the provided text?
Answer: Based on the excerpted language only, the most attackable features are:
- Stoichiometric ratio (claim 5): if not precisely matched by accused product composition
- Salt classification: whether the administered API qualifies as “toluene sulfonic acid addition salt” for claims 4/8/11/12
- Formula limits: any deviation from the parameter set (k/m/n, R1, X, R10, and H substitutions) can defeat literal infringement
Key Takeaways
- US 10,464,938 is primarily a toluene sulfonic acid (tosylate) / toluenesulfonic-acid-including composition patent for a tightly defined Formula 2J chemical entity.
- The core infringement gate is the exact Formula 2J instantiation plus, for dependent claims, the tosylate salt status.
- Method-of-use claims tie administration to 5-HT2 antagonism and 5-HT2A modulation, with method scope shifting by whether the administered API matches the free base, other salt, or tosylate salt embodiments.
- Commercial and generic risk depends on whether any competitor product uses the same Formula 2J and whether toluenesulfonic acid / tosylate is present in the finished product and in the administered API form for method claims.
FAQs
- Does “compound of Formula 2J … or a pharmaceutically acceptable salt thereof” in claim 1 include tosylate automatically even if the compound is a free base (claim 2)?
- How do stoichiometric ratio limitations in claim 5 affect product formulation infringement analysis?
- If a competitor uses a different acid addition salt of the same Formula 2J, does claim 4 still pose method-of-use infringement risk?
- Can a product containing toluenesulfonic acid as an excipient trigger claim 1 even if the API is not converted to the tosylate salt?
- What is the most likely infringement pathway for method-of-use claims versus composition claims under US 10,464,938?
References (APA)
- United States Patent 10,464,938 (claims provided in prompt).
